Cure8 research brief
Obesity in pregnancy was common among people with IBD and was strongly linked to several adverse outcomes that matter to pregnant patients (gestational diabetes, pre‑eclampsia, VTE, emergency cesarean, and large babies). This suggests focusing on obesity and appropriate preventive antenatal care could reduce risks.
Pregnant people with IBD, their partners/caregivers, obstetricians, gastroenterologists, and clinicians involved in antenatal care and VTE prevention.
This study used matched electronic health records to examine first‑trimester obesity prevalence and pregnancy outcomes among women with IBD.
About 22.6% of IBD pregnancies met ethnicity‑adjusted criteria for obesity, and higher obesity class was linked to stepwise increases in gestational diabetes, pre‑eclampsia, venous thromboembolism (VTE), emergency cesarean delivery, and high birthweight.
After propensity‑score matching to non‑IBD pregnancies, obesity was independently associated with a composite adverse pregnancy outcome, while IBD diagnosis alone was not significantly associated with additional risk in this cohort.
The authors note that aspirin was recommended in ~39% of IBD pregnancies and low‑molecular‑weight heparin (LMWH) was prescribed in ~22% of pregnancies classified post hoc as intermediate or high VTE risk.
These findings highlight obesity as an important, potentially modifiable risk factor in pregnancies among people with IBD and suggest opportunities to optimize antenatal preventive prescribing (aspirin/LMWH) where indicated.
This classification and brief are grounded in the article abstract (matched electronic health‑record cohort) provided on PubMed. The study reports associations, not proof of causation. Clinical decisions about aspirin, LMWH, weight management, or other interventions should be made with treating clinicians.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD may face higher-than-expected rates of hypertensive disorders in pregnancy; identifying predictors could help target monitoring and preventive strategies. The study suggests prior HDP and gestational...
Pregnancy outcomes in people with IBD are linked to disease activity and treatment. This study compares outcomes across women who continued, stopped, never used, or started biologics during pregnancy, which can inform...
Some people with IBD and their clinicians consider stopping biologics early in pregnancy to reduce fetal drug exposure. This study suggests stopping before active placental transfer (≈GW20) in women in remission led to a...
